FDA Fast Track speeds Armata (NYSE: ARMP) AP-SA02 bacteremia program
Rhea-AI Filing Summary
Armata Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Fast Track Designation to AP-SA02, its intravenous multi-phage therapy for complicated Staphylococcus aureus bacteremia, including MSSA and MRSA. This status is intended for serious conditions with unmet medical need.
Fast Track allows more frequent FDA interactions, rolling review of a future Biologics License Application, and potential eligibility for Accelerated Approval and Priority Review if supported by clinical data. Armata plans to advance AP-SA02 into a Phase 3 superiority study in complicated bacteremia, anticipated to begin in the second half of 2026, following positive Phase 1b/2a diSArm study results partially backed by a $26.2 million Department of Defense award.
Positive
- FDA Fast Track designation for AP-SA02 supports Armata’s lead bacteriophage program in complicated Staphylococcus aureus bacteremia, enabling more frequent FDA interactions, rolling BLA review, and potential eligibility for Accelerated Approval and Priority Review, which together may shorten the path to potential approval and patient access if Phase 3 results are favorable.
- Non-dilutive funding supports development: The Phase 1b/2a diSArm study of AP-SA02 was partially backed by a $26.2 million Department of Defense award, reducing Armata’s need to fund early clinical work solely from its own balance sheet while advancing a late-stage asset.
Negative
- None.
Insights
FDA Fast Track for AP-SA02 strengthens Armata’s late-stage bacteriophage pipeline.
The FDA granted Fast Track Designation to AP-SA02, Armata’s intravenous multi-phage therapy for complicated Staphylococcus aureus bacteremia, including MSSA and MRSA. Fast Track is reserved for serious conditions with unmet need, signaling regulatory interest in the program’s potential.
The designation enables more frequent FDA engagement, rolling Biologics License Application review, and possible eligibility for Accelerated Approval and Priority Review if clinical data support it. AP-SA02 previously showed positive results in the Phase 1b/2a diSArm study, which was partially funded by a $26.2 million Department of Defense award.
Armata plans a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to start in the second half of 2026. The combination of Fast Track status, prior positive mid-stage data, and non-dilutive DoD funding makes AP-SA02 a central value driver within Armata’s bacteriophage portfolio, though ultimate outcomes still depend on Phase 3 results and regulatory review.
8-K Event Classification
Key Figures
Key Terms
Fast Track Designation regulatory
Biologics License Application regulatory
Accelerated Approval regulatory
Priority Review regulatory
bacteriophage therapeutics medical
current Good Manufacturing Practices technical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of Registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (IRS Employer Identification No.) |
| | |||
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
| Item 7.01 | Regulation FD Disclosure. |
On May 7, 2026, Armata Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release, dated May 7, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 7, 2026 | Armata Pharmaceuticals, Inc. | |
| By: | /s/ David House | |
| Name: | David House | |
| Title: | Senior Vice President, Finance and Principal Financial Officer | |
- 3 -
Exhibit 99.1
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development
Advances AP-SA02 on a faster path to potential approval and patient access
LOS ANGELES, Calif., May 7, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to AP-SA02, the Company's intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate, for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (“MSSA”) or methicillin resistant S. aureus (“MRSA”).
“We are pleased to receive Fast Track designation from the FDA for AP-SA02, which marks another important milestone for this program and underscores both the seriousness of complicated S. aureus bacteremia (“SAB”) and the urgent need for effective new treatment options,” said Dr. Deborah Birx, Chief Executive Officer of Armata Pharmaceuticals. “This designation recognizes the potential of AP-SA02 to improve upon current standard of care treatment options for complicated SAB, a common, extremely severe, and often deadly infection, and highlights the strength of Armata’s phage platform to deliver differentiated therapies for bacterial infections. As we advance toward the initiation of our Phase 3 superiority study, anticipated to begin in the second half of 2026, we remain focused on executing efficiently and look forward to interacting more frequently with the FDA throughout the clinical development and review process, with the goal of bringing this novel antibacterial therapy to patients as quickly as possible.”
Fast Track designation is intended to facilitate the development and expedite the review of investigational therapies that treat serious conditions and fill an unmet medical need. The designation provides for more frequent interactions with the FDA regarding all aspects of a designated drug’s clinical development program, supporting a more efficient path to registration. Fast Track designation also allows for rolling review of a Biologics License Application (“BLA”), meaning completed sections may be submitted and reviewed on an ongoing basis rather than waiting for the full application. Additionally, Fast Track-designated programs may also be eligible for Accelerated Approval and Priority Review if supported by clinical data at the time of BLA submission, further supporting a faster path to potential approval and patient access. For more information on the Fast Track designation, visit the FDA’s official website.
About AP-SA02
Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated Staphylococcus aureus bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin resistant S. aureus (MRSA). The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy (“BAT”) compared to BAT alone (placebo) for the treatment of adults with complicated S. aureus bacteremia. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Phase 1b/2a clinical development of AP-SA02 was partially supported by a $26.2 million Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated S. aureus bacteremia, anticipated to initiate in the second half of 2026.
About Armata Pharmaceuticals, Inc.
Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.
Forward Looking Statements
This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; Armata's planned clinical trials; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the U.S. Securities and Exchange Commission (the “SEC”), including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 25, 2026, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569